Paolo Pucci
Direktor/Vorstandsmitglied bei WEST PHARMACEUTICAL SERVICES, INC.
Vermögen: 4 Mio $ am 30.04.2024
Aktive Positionen von Paolo Pucci
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
WEST PHARMACEUTICAL SERVICES, INC. | Direktor/Vorstandsmitglied | 12.09.2016 | - |
Independent Dir/Board Member | 12.09.2016 | - | |
REPLIMUNE GROUP, INC. | Direktor/Vorstandsmitglied | 01.04.2020 | - |
Independent Dir/Board Member | 01.04.2020 | - | |
MERUS N.V. | Direktor/Vorstandsmitglied | 30.06.2020 | - |
Independent Dir/Board Member | 30.06.2020 | - | |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Direktor/Vorstandsmitglied | 02.12.2020 | - |
Independent Dir/Board Member | 02.12.2020 | - |
Karriereverlauf von Paolo Pucci
Ehemalige bekannte Positionen von Paolo Pucci
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
TRILLIUM THERAPEUTICS | Direktor/Vorstandsmitglied | 12.11.2020 | 17.11.2021 |
Independent Dir/Board Member | 12.11.2020 | 17.11.2021 | |
LUMOS PHARMA, INC. | Direktor/Vorstandsmitglied | 13.11.2015 | 31.10.2018 |
Independent Dir/Board Member | 13.11.2015 | 31.10.2018 | |
DYAX CORP. | Direktor/Vorstandsmitglied | 01.11.2011 | 22.01.2016 |
Independent Dir/Board Member | 01.11.2011 | 22.01.2016 | |
ALGETA ASA | Direktor/Vorstandsmitglied | 11.04.2013 | 01.03.2014 |
BAYER AG | Corporate Officer/Principal | 01.01.2001 | 01.06.2008 |
░░░ ░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Paolo Pucci
Università degli Studi di Napoli Federico II | Undergraduate Degree |
The University of Chicago Booth School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 9 |
Deutschland | 3 |
Kanada | 2 |
Operativ
Director/Board Member | 9 |
Independent Dir/Board Member | 7 |
Corporate Officer/Principal | 4 |
Sektoral
Health Technology | 12 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
BAYER AG | Health Technology |
WEST PHARMACEUTICAL SERVICES, INC. | Health Technology |
MERUS N.V. | Health Technology |
REPLIMUNE GROUP, INC. | Health Technology |
Private Unternehmen | 9 |
---|---|
ArQule, Inc.
ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
Dyax Corp.
Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
NewLink Genetics Corp.
NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Bayer Pharmaceuticals Corp. | |
Trillium Therapeutics ULC
Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Health Technology |
Eli Lilly Sweden AB | |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Algeta ASA
Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Börse
- Insiders
- Paolo Pucci
- Erfahrung